The effect of PTH(1-84) on quality of life in hypoparathyroidism
| Autor: | Amanda Tulley, Mishaela R. Rubin, John P. Bilezikian, Natalie E. Cusano, Dinaz Irani, James Sliney, Donald J. McMahon |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Hypoparathyroidism Endocrinology Diabetes and Metabolism Clinical Biochemistry Parathyroid hormone Reference range Context (language use) Biochemistry Endocrinology Quality of life Internal medicine medicine Humans Social functioning Aged business.industry Endocrine Care Biochemistry (medical) Middle Aged medicine.disease Mental health Recombinant Proteins Parathyroid Hormone Quality of Life Health survey Female business |
| Zdroj: | The Journal of clinical endocrinology and metabolism. 98(6) |
| ISSN: | 1945-7197 |
| Popis: | Complaints from hypoparathyroid patients often reflect a reduction in quality of life (QOL), yet few data exist characterizing these complaints or the potential effects of PTH therapy to ameliorate them.We tested the hypothesis that PTH(1-84) therapy improves QOL in hypoparathyroidism.Fifty-four hypoparathyroid subjects received open-label recombinant human PTH(1-84). Before and during PTH(1-84), subjects completed the RAND 36-Item Health Survey, a measure of health-related QOL covering 8 domains of physical and mental health.At baseline, subjects scored significantly lower than the normative reference range in all 8 domains (T-scores -1.35 to -0.78; P0.001 for all). With PTH(1-84), the total score improved as early as month 1 and remained higher through 1 year (400 ± 200 to 478 ± 230; P = 0.001). The overall mental component summary score improved (204 ± 110 to 247 ± 130; P = 0.001), as did 3 mental health domains (vitality, social functioning, and mental health), all within 1 month (T-scores improving from -1.3 to -0.7, -1.0 to -0.6, and -0.9 to -0.3, respectively; P0.05 for all). The overall physical component summary score also increased by 1 month and remained higher at 1 year (196 ± 110 to 231 ± 130; P = 0.003) as did 2 physical health domains (physical functioning and general health: T-scores improving from -0.8 to -0.4, -1.2 to -0.8, respectively; P0.01 for both).These data suggest that hypoparathyroidism is associated with compromised QOL. Along with improved biochemical control, these results indicate that PTH(1-84) treatment of hypoparathyroidism improves physical and mental functioning. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|